Li Juan, Ren Luo, Liu Jiao, Tang Yuyi, Wang Run, Yang Peixin, Zhao Jing, Chen Xiao, Xiang Zheng, Zhong Wen, Zang Na, Chen Dapeng, Fang Heping, Liu Enmei
Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Key Laboratory of Children's Important Organ Development and Diseases of Chongqing Municipal Health Commission, Chongqing, China.
Children's Hospital of Chongqing Medical University, Pediatric Research Institute, Chongqing, China.
J Med Internet Res. 2025 Oct 30;27:e78693. doi: 10.2196/78693.
Childhood asthma, particularly in early life, is often underdiagnosed and poorly characterized in real-world outpatient settings due to diagnostic challenges and resource constraints. A pragmatic, scientifically rigorous, prospective cohort model is urgently needed.
We aimed to establish and present a cross-sectional baseline analysis of the Clinical Registry of Childhood Asthma, a prospective, longitudinal, and digitally enhanced cohort in outpatient settings, focusing on the diagnostic spectrum of early-life asthma.
We established the Clinical Registry of Childhood Asthma cohort and performed a cross-sectional analysis of its baseline data. We launched the cohort in March 2024 as an ongoing study, enrolling children (<18 years) with persistent cough and wheezing from a tertiary pediatric referral center in Southwest China. The study used a real-world design, integrating symptom-driven recruitment with standardized electronic medical records, structured electronic patient-reported outcomes, and systematic biobanking of residual biospecimens. Participants were classified as having confirmed, suspected, or excluded asthma based on cross-sectional baseline data.
From March 2024 to August 2025, we enrolled 396 children (median age 4.7 years) from 2296 outpatient visits (enrollment rate 17.2%). Follow-up rates were 26.7% and 43.3% at first and second timepoints, respectively. A comprehensive biorepository was established with serum, plasma, PBMCs, and other blood cell samples (average coverage 74.0%). Most children (267/396, 67.4%) were under 6 years. Patients were stratified into confirmed (131/396, 33.1%), suspected (179/396, 45.2%), and excluded asthma (86/396, 21.7%). Suspected and excluded cases were significantly younger than confirmed cases (median 4.1/3.9 vs 6.6 years, P<.001). Comorbidity profiles differed significantly: allergic rhinitis prevailed in confirmed asthma (77/131, 58.8%), while chronic cough (64/86, 74.4%) and bronchitis (39/86, 45.3%) dominated the excluded group. Type 2 inflammation biomarkers also differed across groups, including aeroallergen sensitization, blood eosinophil count, and fractional exhaled nitric oxide (P<.001). Physician-parent diagnostic discordance was most pronounced in suspected asthma (76/134, 56.7%, P<.001). Multivariable analyses showed suspected asthma (vs excluded) was associated with respiratory infection as wheezing trigger (odds ratio [OR] 4.41, 95% CI 2.16-9.42, P<.001), family history of allergic rhinitis (OR 2.27, 95% CI 1.08-4.99, P=.03), and higher blood eosinophil count (OR 1.32 per 100 cells/μL, 95% CI 1.05-1.73, P=.02). Confirmed asthma (vs suspected) was associated with older age (OR 1.29 per year, 95% CI 1.14-1.47, P<.001), allergic rhinitis (OR 4.06, 95% CI 1.99-8.31, P<.001), and aeroallergen sensitization (OR 3.83, 95% CI 1.91-7.66, P<.001). Bronchitis was negatively associated with an asthma diagnosis across models (OR 0.30 for suspected vs excluded; OR 0.21 for confirmed vs suspected; OR 0.13 for confirmed vs excluded).
The Clinical Registry of Childhood Asthma establishes a feasible cohort in outpatient settings that captures the diagnostic uncertainty of early-life asthma. It identifies a distinct suspected asthma subgroup and reveals significant patient-clinician diagnostic discordance, providing a valuable resource for improving disease management.
儿童哮喘,尤其是在生命早期,在现实世界的门诊环境中常常因诊断挑战和资源限制而诊断不足且特征描述不佳。迫切需要一种实用、科学严谨的前瞻性队列模型。
我们旨在建立并展示儿童哮喘临床登记处的横断面基线分析,这是一个在门诊环境中的前瞻性、纵向且数字化增强的队列,重点关注生命早期哮喘的诊断范围。
我们建立了儿童哮喘队列临床登记处,并对其基线数据进行了横断面分析。我们于2024年3月启动该队列作为一项正在进行的研究,从中国西南部一家三级儿科转诊中心招募持续咳嗽和喘息的儿童(<18岁)。该研究采用现实世界设计,将症状驱动的招募与标准化电子病历、结构化电子患者报告结局以及残余生物标本的系统生物样本库相结合。根据横断面基线数据,参与者被分类为确诊、疑似或排除哮喘。
从2024年3月到2025年8月,我们从2296次门诊就诊中招募了396名儿童(中位年龄4.7岁)(招募率17.2%)。第一次和第二次时间点的随访率分别为26.7%和43.3%。建立了一个包含血清、血浆、外周血单核细胞和其他血细胞样本的综合生物样本库(平均覆盖率74.0%)。大多数儿童(267/396,67.4%)年龄在6岁以下。患者被分层为确诊(131/396,33.1%)、疑似(179/396,45.2%)和排除哮喘(86/396,21.7%)。疑似和排除病例明显比确诊病例年轻(中位年龄4.1/3.9岁对6.6岁,P<.001)。合并症情况有显著差异:过敏性鼻炎在确诊哮喘中占主导(77/131,58.8%),而慢性咳嗽(64/86,74.4%)和支气管炎(39/86,45.3%)在排除组中占主导。2型炎症生物标志物在各组之间也有所不同,包括气传变应原致敏、血嗜酸性粒细胞计数和呼出一氧化氮分数(P<.001)。医生与家长的诊断不一致在疑似哮喘中最为明显(76/134,56.7%,P<.001)。多变量分析显示,疑似哮喘(与排除相比)与呼吸道感染作为喘息触发因素相关(比值比[OR]4.41,95%置信区间2.16 - 9.42,P<.001)、过敏性鼻炎家族史(OR 2.27,95%置信区间1.08 - 4.99,P=.03)以及更高的血嗜酸性粒细胞计数(每100个细胞/μL OR 1.32,95%置信区间1.05 - 1.73,P=.02)。确诊哮喘(与疑似相比)与年龄较大相关(每年OR 1.29,95%置信区间1.14 - 1.47,P<.001)、过敏性鼻炎(OR 4.06,95%置信区间1.99 - 8.31,P<.001)和气传变应原致敏(OR 3.83,95%置信区间1.91 - 7.66,P<.001)。在所有模型中,支气管炎与哮喘诊断呈负相关(疑似与排除相比OR 0.30;确诊与疑似相比OR 0.21;确诊与排除相比OR 0.13)。
儿童哮喘临床登记处在门诊环境中建立了一个可行的队列,捕捉了生命早期哮喘的诊断不确定性。它识别出一个独特的疑似哮喘亚组,并揭示了患者与临床医生之间显著的诊断不一致,为改善疾病管理提供了宝贵资源。